Back

Combined MGMT Expression and MMR Deficiency Underlie Poor Outcomes of Temozolomide in IDH-Wildtype Grade 2 Gliomas

2025-12-15 oncology Title + abstract only
View on medRxiv
Show abstract

BackgroundIsocitrate dehydrogenase wildtype (IDHwt) histologic grade 2 adult diffuse gliomas represent a highly heterogeneous entity, and the effects of postoperative adjuvant temozolomide (TMZ) therapy, as well as the predictive value of chemotherapy-related biomarker O6-methylguanine-DNA methyltransferase promoter (MGMT-p) methylation, remain to be further investigated. MethodsA Discovery dataset, comprising 108 IDHwt histologic grade 2 gliomas obtained from three public resources, was constr...

Predicted journal destinations